Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by ...

Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory ...

In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also ...

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, explains how GLP-1 therapies’ success can influence future investment ...

In a recent interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, discussed how AI is transforming clinical trials by reducing costs, accelerating timelines, and enhancing ...

Ruth Beadle, head, global supply chain, Sanofi, discusses how digital integration, advanced planning, and sustainability goals are transforming end-to-end supply chain operations to improve scale, ...

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

In the third part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, dives into the barriers limiting AI and automation’s widespread adoption in R&D ...